CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use
- 1 September 2005
- journal article
- Published by BMJ in International Journal of Gynecologic Cancer
- Vol. 15 (5), 679-691
- https://doi.org/10.1111/j.1525-1438.2005.00130.x
Abstract
CA125 is currently the most widely used tumor marker for ovarian epithelial cancer. The aim of this article is to provide guidelines for the routine clinical use of CA125 in patients with ovarian cancer. Due to lack of sensitivity for stage I disease and lack of specificity, CA125 is of little value in the detection of early ovarian cancer. At present, therefore, CA125, either alone or in combination with other modalities, cannot be recommended for screening for ovarian cancer in asymptomatic women outside the context of a randomized controlled trial. Preoperative levels in postmenopausal women, however, may aid the differentiation of benign and malignant pelvic masses. Serial levels during chemotherapy for ovarian cancer are useful for assessing response to treatment. Although serial monitoring following initial chemotherapy can lead to the early detection of recurrent disease, the clinical value of this lead-time is unclear. CA125 is the ovarian cancer marker against which new markers for this malignancy should be judged.Keywords
This publication has 65 references indexed in Scilit:
- Calculation of the Risk of Ovarian Cancer From Serial CA-125 Values for Preclinical Detection in Postmenopausal WomenJournal of Clinical Oncology, 2003
- Ovarian cancer: progress and continuing controversies in managementEuropean Journal of Cancer, 2002
- The performance of screening tests for ovarian cancer: results of a systematic reviewBJOG: An International Journal of Obstetrics and Gynaecology, 1998
- CA 125 kinetics: A cost-effective clinical tool to evaluate clinical trial outcomes in the 1990sAmerican Journal of Obstetrics and Gynecology, 1996
- Serum tumor marker immunoassays in gynecologic oncology: Establishment of reference valuesAmerican Journal of Obstetrics and Gynecology, 1996
- Markers Supplementing CA 125 in Ovarian CancerAnnals of Medicine, 1995
- Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass. An international multicenter studyCancer, 1994
- National survey of ovarian carcinoma part V. The impact of physician's specialty on patients' survivalCancer, 1993
- CA 125 in the diagnosis of pelvic massesEuropean Journal of Cancer and Clinical Oncology, 1989
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983